Malaysia’s National Immunization Programme (NIP) chose Pfizer, AstraZeneca (AZ) and Sinovac as its vaccine portfolio. At the outset, Beijing assured…

This policy brief assesses COVID-19’s impact on travel and tourism in Asia and the Pacific and outlines a set of expert-reviewed policy recommendations…

In Asia, where rapid urbanization is occurring, inadequate water and sanitation services are a problem due to insufficient investment. Asia’s…

In the second quarter of 2021, rising COVID-19 cases have cast a shadow over emerging East Asia's growth outlook. Yet the region's financial…